Please login to the form below

Case study: Opportunity Assessment for a Rare Disease Product in Emerging Markets

Using in-depth-interviews to determine how to maximise the commercial opportunities in different emerging markets
We have recently produced a guide to conducting effective market research in rare diseases, based on our experience in a broad number of disease areas.

Our client had a product indicated for a rare Haematology disease. Whilst this product was successfully launched in over 40 countries globally, it had a limited presence in many emerging markets. Our client needed to conduct market research in order to determine how to maximise the commercial opportunities in each of these different emerging markets.

Read the full case study here:
http://www.researchpartnership.com/news/2015/11/case-study-opportunity-assessment-for-a-rare-disease...  

6th January 2016

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Healthcare in the age of AI: How will artificial intelligence impact future decision-making?
Authored by: Constanza Salas, Jhon Galindo and Rachel Howard
Research Partnership
Therapy Watch launches new tracker covering Postpartum Depression
The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry
Research Partnership
Value-based pricing reform: Strengthening the ‘front door’ to the Colombian pharmaceutical market
Authored by: Marc Garcia and Tania Rodrigues
Research Partnership
Infographic: Rare Diseases in China
How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.
Research Partnership
New syndicated COPD report now available
Living with COPD 2023
Research Partnership
Man vs microbe: the fight against antimicrobial resistance
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.
Research Partnership